What are you smoking? Any negative net income (net loss) means there was a negative margin. Profit Margin is net income divided by revenues. Are you somehow, referring to some other type of margin? If so you should provide more clarification. Like it or not, JCOF is STILL overvalued at .20 cents. They need to make 600 million in revs a year before it's valued at .20 cents. So, I don't care how much your revs go up, @ 4% which is across the board for most MLMs as profit margin, those earnings need to exist to make a difference, and the revs need to be sky high, while other factors stay the same, to justify .20. Let alone going up from there. It's still overvalued, like it or not. So many of us have been saying this for OVER a year now, and people still don't listen. So many have fallen in love with the stock and will never, ever listen.
Who compares steak to linguini? Developmental biotechs with no margin to work off of are not priced based on margin, they are priced based on cash flow/cash level, markets and population samples, THEN a multiplier. You can see an example of that equation, here: http://messages.finance.yahoo.com/Business_%26_Finance/Investments/Stocks_%28A_to_Z%29/Stocks_Y/threadview?bn=22264&tid=30807&mid=30807 You may also want to take into consideration that the majority of biotechs become hyped way before drug release, only to suffer 20%+ losses almost every single time after the first drug is released. Example INCY last week 20%, DNDN 65%, KERX 75%, etc. Once again, because people have no idea how to price a stock, AND DONT LISTEN TO THOSE WHO DO KNOW. ;) You should at least have the common sense to detect a trend by now at which revenues increase, and realize that it will take about a whole year before they can reach the revenues necessary to hold a margin of 4% stable. Therefore, JCOF is not CURRENTLY a great investment, not without a massive restructure.